P2 receptors and cancer
- PMID: 16530853
- DOI: 10.1016/j.tips.2006.02.004
P2 receptors and cancer
Abstract
Purinergic signalling has been implicated in many biological processes, and ATP and other extracellular nucleotides might have therapeutic potential in the treatment of cancer by signalling through P2 receptors. Different P2 receptor subtypes have been identified in a variety of different cancer types, in both primary samples of human cancer tissue and cell lines. Recent evidence suggests that different receptor subtypes mediate different pathophysiological functions such as proliferation, differentiation and apoptosis. In vivo studies of the use of ATP suggest that it can decrease the rate of cancer growth, and the first clinical trials have been undertaken. Thus, agents acting at P2 receptors might provide novel therapeutic tools in the treatment of cancer. In this article, background information about purinergic signalling and purinoceptor subtypes will be provided and then the proposed role of ATP in different cancers will be discussed in detail, including a discussion of in vivo studies and animal models, clinical trials and the specific P2 receptor subtypes involved.
Similar articles
-
Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer.BJU Int. 2008 Feb;101(3):352-9. doi: 10.1111/j.1464-410X.2007.07293.x. Epub 2007 Nov 13. BJU Int. 2008. PMID: 18005209
-
A comparative study of ectonucleotidase and P2 receptor mRNA profiles in C6 cell line cultures and C6 ex vivo glioma model.Cell Tissue Res. 2009 Feb;335(2):331-40. doi: 10.1007/s00441-008-0723-4. Epub 2008 Nov 21. Cell Tissue Res. 2009. PMID: 19023597
-
Purinergic receptor-mediated effects of ATP in high-grade bladder cancer.BJU Int. 2008 Jan;101(1):106-12. doi: 10.1111/j.1464-410X.2007.07286.x. Epub 2007 Oct 17. BJU Int. 2008. PMID: 17941929
-
Involvement of P2 receptors in the growth and survival of neurons in the CNS.Pharmacol Ther. 2006 Mar;109(3):297-324. doi: 10.1016/j.pharmthera.2005.06.002. Epub 2005 Aug 15. Pharmacol Ther. 2006. PMID: 16102837 Review.
-
New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.J Natl Compr Canc Netw. 2003 Jan;1 Suppl 1:S78-86. J Natl Compr Canc Netw. 2003. PMID: 19795580 Review.
Cited by
-
Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses.Purinergic Signal. 2013 Sep;9(3):285-306. doi: 10.1007/s11302-013-9357-4. Epub 2013 Feb 13. Purinergic Signal. 2013. PMID: 23404828 Free PMC article. Review.
-
Purinergic signaling during inflammation.N Engl J Med. 2012 Dec 13;367(24):2322-33. doi: 10.1056/NEJMra1205750. N Engl J Med. 2012. PMID: 23234515 Free PMC article. Review. No abstract available.
-
Synthetic Strategies for Dinucleotides Synthesis.Molecules. 2019 Nov 27;24(23):4334. doi: 10.3390/molecules24234334. Molecules. 2019. PMID: 31783537 Free PMC article. Review.
-
Long-term (trophic) purinergic signalling: purinoceptors control cell proliferation, differentiation and death.Cell Death Dis. 2010;1(1):e9. doi: 10.1038/cddis.2009.11. Cell Death Dis. 2010. PMID: 21364628 Free PMC article. Review.
-
Purinergic regulation of vascular endothelial growth factor signaling in angiogenesis.Br J Cancer. 2009 May 5;100(9):1465-70. doi: 10.1038/sj.bjc.6604998. Epub 2009 Apr 14. Br J Cancer. 2009. PMID: 19367276 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
